Completed
Dose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia
What is being tested
Limicol
+ Placebo
Dietary SupplementOther
Who is being recruted
Arterial Occlusive Diseases+11
+ Arteriosclerosis
+ Cardiovascular Diseases
From 18 to 65 Years
+5 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-Controlled
Interventional
Study Start: April 2011
Summary
Principal SponsorLescuyer Laboratory
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: April 1, 2011
Actual date on which the first participant was enrolled.The principal objective of this study is to investigate the dose-effect of the Limicol food supplement on LDL-cholesterol level in moderate hypercholesterolaemia subjects.
Official TitleDose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia
Principal SponsorLescuyer Laboratory
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
45 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Arterial Occlusive DiseasesArteriosclerosisCardiovascular DiseasesCoronary Artery DiseaseCoronary DiseaseHeart DiseasesHypercholesterolemiaHyperlipidemiasMetabolic DiseasesNutritional and Metabolic DiseasesVascular DiseasesMyocardial IschemiaDyslipidemiasLipid Metabolism Disorders
Criteria
5 inclusion criteria required to participate
About 18 to 65 years (inclusive).
Subject has a stable weight for at least three months before the start of the study.
Subject able and willing to comply with the protocol and agreeing to give their consent in writing.
Subject affiliated with a social security scheme.
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center